Clinical Scorecard: A Roadmap for Organoid Toxicology

At a Glance

Key Highlights

• CIVMs bridge the gap between simple cell cultures and human biology.
• AI algorithms can automate assessment of single-cell toxicities.
• 3D models better reproduce tissue architecture and cellular interactions.
• Collaboration among bioengineers, biologists, and pathologists is crucial.
• Formalin-fixed, paraffin-embedded processing preserves morphology for digital pathology.

Guideline-Based Recommendations

Diagnosis

• Utilize multiplex immunohistochemistry and spatial assays for organoid validation.

Management

• Adopt algorithm-supported analysis to standardize histopathology evaluations.

Monitoring & Follow-up

• Implement high-resolution 2D sections for increased throughput in assessments.

Risks

• Traditional 2D cultures and animal models may not accurately reflect human responses.

Patient & Prescribing Data

Not specified; relevant to drug development and testing.

Potential for patient-derived samples to enhance relevance in drug testing.

Clinical Best Practices

• Establish interdisciplinary teams for organoid development and assessment.
• Focus on rigorous characterization and validation of organoids.
• Utilize AI to reduce variability in histopathology evaluations.

References